New combo pill cocktail targets tough prostate cancer

NCT ID NCT06689163

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests a new drug, HRS-1167, combined with two standard treatments (abiraterone and prednisone) in men with metastatic prostate cancer that has spread. The goal is to find the best dose and see if the combination is safe and helps control the disease. About 66 men aged 18 and older with confirmed prostate cancer and good performance status are being recruited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
The First Affiliated Hospital Of Anhui Medical University
RECRUITING

Hefei, Anhui, 230000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER